Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LHT344 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| LHT344 | DRUG | - |
Inclusion Criteria: * Healthy, non-smoking, male or female subjects age 18 to 45 years of age * In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation * Body mass index within the range o...
LHT344 is an investigational small molecule being developed by Novartis AG. It is currently in Phase 1 clinical development. The only completed trial for LHT344 was a safety and pharmacokinetics study in healthy subjects in China.
LHT344 is being studied for use in healthy subjects. The completed Phase 1 trial evaluated its safety and pharmacokinetics in healthy Chinese volunteers. It is not approved for any medical condition and remains in clinical development.
LHT344 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company conducted a Phase 1 clinical trial of LHT344 in healthy subjects.
LHT344 is in Phase 1 clinical development. A Phase 1 trial, NCT00414778, has been completed. This trial was a safety and pharmacokinetics study in healthy subjects. LHT344 is not yet approved and is still in the early stages of clinical testing.
LHT344 has one completed clinical trial, NCT00414778, titled 'Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects.' This Phase 1 study enrolled 12 healthy volunteers in China and was not randomized or blinded.